🇺🇸 PTCT — PTC Therapeutics, Inc.

Salud Compra
← Volver

Precio actual

68,12 USD

Máx. histórico

89,55

117 días

Caída desde máximo

-23,93%

Rango 52 semanas

58,80 – 90,87

Variación hoy

+11,89%

Cierre anterior

60,88

Rango de hoy

63,16 – 68,72

Volumen hoy

2.643.738

Peor caída histórica

-94,60%

17/03/2015 → 03/11/2016

Recuperado en 3305 días

Volatilidad anualizada ⓘ

72,99%

Información
Nombre completo
PTC Therapeutics, Inc.
Divisa
USD
Mercado
NasdaqGS
Sector
Salud
Industria
Biotechnology
Empleados
991
PER ⓘ
—
Dividend yield
0,00% (puede no estar actualizado)
Precio objetivo analistas
100,47 USD (puede no estar actualizado)
Primera cotización
20/06/2013
Precio actualizado
hace 5 horas
Sobre la empresa

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to children and adults living with rare disorders in the United States and internationally. The company provides Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and inflammation and ferroptosis platforms, including vatiquinone to treat Friedreich's ataxia. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd., Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. The company has license and collaboration agreement with Novartis Pharmaceuticals Corporation to develop PTC518 Huntington's disease program. It markets Upstaza, a gene therapy with the brand name Kebilidi in the United States. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in Warren, New Jersey.

Rentabilidad mensual
Evolución
Histórico día a día
Fecha Apertura Máximo Mínimo Cierre Variación Volatilidad día Volumen
17/01/2025 43,31 44,55 42,18 43,84 +1,76% 5,47% 950.000
16/01/2025 42,00 43,16 41,75 43,08 +1,92% 3,36% 464.000
15/01/2025 42,92 44,32 41,87 42,27 +1,10% 5,71% 530.900
14/01/2025 43,67 44,69 41,67 41,81 -5,09% 6,93% 920.000
13/01/2025 43,50 44,92 42,35 44,05 +0,25% 5,91% 685.000
10/01/2025 43,68 45,59 43,63 43,94 -2,44% 4,49% 548.600
08/01/2025 43,99 45,27 43,50 45,04 +0,96% 4,02% 615.900
07/01/2025 45,85 47,00 44,37 44,61 -2,56% 5,74% 577.700
06/01/2025 46,08 46,71 45,73 45,78 -1,63% 2,14% 456.800
03/01/2025 45,96 46,73 45,83 46,54 +1,44% 1,96% 501.600
02/01/2025 46,17 47,06 45,47 45,88 +1,64% 3,44% 474.400
31/12/2024 45,86 46,79 44,71 45,14 -1,38% 4,54% 360.000
30/12/2024 44,70 45,95 44,58 45,77 +1,19% 3,06% 555.500
27/12/2024 45,34 46,11 44,70 45,23 -1,33% 3,11% 346.600
26/12/2024 45,08 46,22 45,03 45,84 +1,08% 2,64% 278.500
24/12/2024 45,56 46,15 44,95 45,35 -0,46% 2,63% 185.800
23/12/2024 46,09 46,23 44,52 45,56 -1,47% 3,71% 425.700
20/12/2024 44,77 47,42 44,74 46,24 +2,19% 5,99% 1.431.600
19/12/2024 45,66 46,56 44,97 45,25 -0,46% 3,48% 575.400
18/12/2024 47,51 48,04 44,30 45,46 -3,32% 7,86% 602.400
17/12/2024 47,77 48,61 46,66 47,02 -3,27% 4,07% 496.800
16/12/2024 46,30 48,77 46,00 48,61 +4,83% 5,98% 626.100
13/12/2024 49,34 49,35 46,33 46,37 -2,09% 6,12% 666.200
12/12/2024 49,52 49,89 47,03 47,36 -4,65% 5,78% 622.300
11/12/2024 50,00 50,20 49,06 49,67 -0,64% 2,28% 471.100
10/12/2024 50,00 51,74 49,44 49,99 +4,02% 4,60% 859.700
09/12/2024 47,54 48,55 46,66 48,06 +0,04% 3,98% 887.800
06/12/2024 48,00 49,44 47,88 48,04 -0,74% 3,25% 481.900
05/12/2024 48,53 49,50 47,75 48,40 -2,93% 3,61% 596.800
04/12/2024 49,89 51,62 49,41 49,86 -0,86% 4,43% 941.500